ABSTRACT. A full-length cDNA sequence of canine Na-dependent neutral amino acid transporter (ASCT2) and its distribution were determined. The sequence was 2,090 bp long and was predicted to encode 544 amino acid polypeptides. The amino acid sequence deduced from canine ASCT2 showed 90% similarity to that of humans and mice. Northern blot analysis revealed ASCT2 expression in the kidney, heart, lung and muscles, and Western blot analysis using anti-human ASCT2 antiserum detected the bands at 60 and 65 kDa in membrane protein of the lung. RT-PCR analysis revealed ASCT2 expression in all the tissues examined.
Many amino acid transport systems have been distinguished based on differences in their substrate selectivity, ion dependence, pH sensitivity, and kinetics and regulatory properties, using a membrane vesicle preparation or cultured cells [4] . Among them, system ASC was designated as a transporter of alanine, serine and cysteine, along with other small neutral amino acids. This designation is now attributed to 2 Na + -dependent transporters termed ASCT1 and ASCT2 (System ASC amino acid transporters 1 and 2, respectively), which belong to the SLC1 gene family [10, 18] . ASCT2 was firstly isolated from a cDNA library constructed from a human placental choriocarcinoma cell line using human ASCT1 cDNA as a probe, and was called hATB 0 , which stands for human amino acid transporter B 0 , because of its functional similarities to a transport activity previously characterized on polarized epithelial cells termed System B 0 [11] .
The cell-growth rate and biosynthesis of DNA and protein are directly correlated with glutamine concentration [22] , and glutamine uptake is mediated primarily through ASCT2 [1, 2, 5, 21 ]. An increased expression of ASCT2 has also been documented in several types of primary tumors [14, 23] . Experimental evidence has shown that the ASCT2 gene is expressed in and mediates most of the glutamine uptake in human hepatoma, breast carcinoma, neuroblastoma, colon carcinoma, and C6 glioma cell lines [1, 2, 4, 5, 11, 12, 17, 20, 21] . In spite of the importance of ASCT2 in cell growth and proliferation, little information has been available regarding the molecular structure and function of canine ASCT2. Therefore, we determined the cDNA sequence of canine ASCT2 and examined its distribution in the tissues of healthy dogs as the first step in evaluating the ASCT2 function in canine cells.
All experiments were performed according to the guidelines of the Laboratory Animal Care Committee of Azabu University, and were in compliance with the Fundamental Guidelines for Proper Conduct of Animal Experiment and Related Activities in Academic Research Institutions. The cancer sample was provided by Animal Teaching Hospital of Azabu University, and histological examination was conducted in the pathology section of the hospital. Total RNA was isolated from the canine lung using an RNA extraction solution (Isogen, Nippon Gene, Tokyo, Japan). The primers used for the amplification of partial canine ASCT2 cDNA were prepared from the conserved region sequences between humans and mice (accession No. GQ919058 and D85044, respectively). RT-PCR amplification was performed using a SuperScriptIII First-Strand cDNA Synthesis System kit (Invitrogen, Carlsbad, CA, U.S.A.) with Hot Start Ex Taq DNA Polymerase (Takara, Kyoto, Japan). The band was excised from the agarose gel and purified using a Wizard SV Gel Clean-Up System (Promega, Madison, WI, U.S.A.). The extracted and purified DNA was cloned into a pCR II-TOPO cloning vector (Invitrogen, Carlsbad, CA, U.S.A.) and sequenced with a BigDye Terminator kit ver.3 (Applied Biosystems, Carlsbad, CA, U.S.A.). The nucleotide sequence obtained exhibited high similarity (90%) to that of human ASCT2. In order to determine the 3′ and 5′ regions of cDNA, RACE methods were carried out using a SMARTer RACE cDNA Amplification kit (Takara, Kyoto, Japan) and a set of canine ASCT2 gene-specific primers (GSP1 and GSP2, Fig. 1 ). The nucleotide sequence obtained (DDBJ accession number AB635686), corresponding to a full-length canine ASCT2 cDNA, was 2,090 bp in length and contained an entire open reading frame of 1,455 bp, encoding canine ASCT2 of 544 amino acids and having a theoretical mass of 57 kDa. To determine the genomic structure, the UCSC genome browser site (http://genome.ucsc.edu/) was used to align canine genomic sequences and the cDNA sequence of ASCT2.
The deduced amino acid sequence of ASCT2 showed high (90%) similarities to that of humans and mice, while the Nterminus region of ASCT2 was diverse among mammals (Fig.  2 ). There were some differences in the amino acid sequence of canine ASCT2 compared with those of humans and mice. In canines, there were 3 amino acid insertions at 314-316 and one amino acid deletion from 536-537, which were not observed in humans and mice. In canines and humans, there were 4 regions (165-166, 212-213, 217-218 and 225-226) of amino acid deletion that were not found in mice. Potential protein kinase C-dependent phosphorylation sites are located at residues 333 (TRK). There were 4 potential casein kinase II sites at 184 (SFLD), 207 (TTYE), 262 (SFND) and 498 (SVPE). In addition, potential N-linked glycosylation sites were observed at residues 164 (NASA) and 215 (NGTM). Northern blot analysis was carried out using 2 µg of mRNA of each tissue sample purified with oligo-(dT) cellulose. The gels were transferred to a Hybond-XL filter (GE Healthcare Bioscience, Piscataway, NJ, U.S.A.) and hybridized with a Fig. 2 . Amino acid sequences of canine ASCT2 compared with those of humans and mice. Multiple sequence alignments were performed using the GENETYX software (ver. 10). Asterisks and dots indicate identical residues and conservative substitutions, respectively. Potential casein kinase II-dependent phosphorylation sites, protein kinase C-dependent phosphorylation sites and glycosylation sites were labeled with †, ‡ and #, respectively (A). Kyte-Doolittle hydropathy analysis indicated multiple hydrophobic regions. The protein contained seven prominent hydrophobic domains, and a long hydrophobic stretch (LHS).
probe containing the center region of canine ASCT2. The DNA fragment used for the probe was labeled with [α− 32 P] dCTP using the Megaprime DNA Labeling System and the illustra NICK Columns (GE Healthcare Bioscience). After hybridization, the membrane was washed three times in 2 × SSC and 0.1% SDS at 65°C. Radioactivity was visualized by autoradiography using the FLA-2000 digital imaging system (Fujifilm, Tokyo, Japan). As indicated in Fig. 3 , a distinct signal was observed in the lung and kidney, and a weak one was observed in the heart and muscle. It was reported that mouse ASCT2 was observed in the lung, skeletal muscle, kidney and testis, but not in the heart by Northern blot analysis [20] . Therefore, it was revealed that there was a difference in ASCT2 expression in the heart and testis between mammals. In addition, ASCT2 was reported to be significantin rat cardiomyocytes [14] . Detailed investigation of ASCT2 expression in the canine heart is necessary. RT-PCR analysis was performed using designed primers specific to canine ASCT2 (sense, 5′-catgggctcctcgtgctgcccctcatc-3′; anti sense, 5′-gaacgggcagactgactgcctccaggat -3′, expected DNA size: 406 bp) using the Superscript III first-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA, U.S.A.), according to the manufacturer's instructions. The RT-PCR conditions were as follows: 30 cycles of 94°C for 15 sec, 65°C for 30 sec and 72°C for 30 sec. Figure 4 shows the RT-PCR analysis of ASCT2 (A) mRNA in various tissues from dogs and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (B). Discrete bands 406 bp in length were observed in all tissues examined, while those in the liver and spleen were relatively weak. Notably, a cancer cell sample originating from the liver exhibited potent ASCT2 expression compared with normal liver tissue. Protein expressions of ASCT2 were investigated by Western blot analysis. The cell membrane of each tissue was prepared as reported previously [16] . In brief, canine tissues were homogenized at 4°C in a buffer containing 0.1 M KCl, 5 mM Na 2 HPO 4 (pH 7.5), 0.75 mM Na-EGTA (pH 7.5), 1 mM DDT, 5 mM MgCl 2 , 200 µg/ml phenylmethylsulfonyl fluoride, and 4 µg/ml leupeptin. Homogenates were centrifuged for 10 min to remove debris. The supernatant was laid over the sucrose solution containing 0.8 mM sucrose and 2 mM Na-EGTA, and was centrifuged at 32,000 × g for 40 min. The protein concentration of the pellet was determined by the BCA method. The membrane protein was electrophoresed into 12% polyacrylamide gels, and immunoblotted. It was then treated with the primary antibody (SLC1A5 Rabbit anti-Human Polyclonal Antibody (Cat. ID LS-C31887), 1:2,000, Lifespan Biosciences, Seattle, WA, U.S.A.), followed by a secondary antibody (anti-rabbit IgG (H+L) goat IgG Fab' HRP, 1:20,000, Seikagaku Corp., Tokyo, Japan). The ASCT2 protein was detected with an ECL Plus a chemiluminescence detection system (GE Healthcare Bioscience), and was exposed to Hyperfilm ECL. As indicated in Fig. 4C , Western blot analysis using anti-human ASCT2 revealed two distinct bands at 60 kDa and 65 kDa. Treatment with N-glycosidase F (Roche Diagnostic, Basel, Switzerland) at 37°C for 6 hr did not reduce the molecular weight of the bands (data not shown), and it was reported that the N-terminus truncated the form of ASCT2 was isolated from a human lymphocyte cDNA library [19] . Therefore, it was speculated that detection of two bands was not caused by glycosylation, but was caused by the existence of a truncated form as humans.
In this report, we determined the full-length cDNA sequence of canine ASCT2 (the Na-dependent neutral amino acid transporter), and examined its expression in various canine tissues. The sequence possessed a high homology with ASCT2 reported elsewhere, and the motif of the amino acid sequence was well conserved compared with other mammals. The sequence was 2,090 bp long and was predicted to encode 544 amino acid polypeptides, which showed a 90% similarity to that of humans and mice. Northern blot analysis indicated that ASCT2 was detected in the lung and kidney and weakly in the heart and muscle (Fig. 3 ). There were some differences in ASCT2 expression between dog and mouse. In the mouse, ASCT2 expression was observed in the testis, but not in the heart [20] . Although RT-PCR analysis showed that certain signals were detected in all tissues examined, those of the liver and spleen were relatively weak (Fig. 4A) . This discrepancy between Northern blot and RT-PCR may due to the sensitivity of each system. Western blot analysis using anti-human ASCT2 anti-serum indicated two distinct bands at 65 and 60 kDa in the membrane protein of the lung, which may be attributable to the existence of a truncated ASCT2 form. Notably, a cancer cell sample originating from the liver exhibited potent ASCT2 expression. While the number of samples tested was not enough, upregulation of ASCT2 was confirmed in cancer cells in canine. ASCT2 is an important amino acid transporter that provides cells with amino acids for cellular metabolism and nutrition, and it was thought to exist in the basolateral membrane to transport amino acids from blood to epithelial cells to nourish epithelial cells. Regardless of their origin, cancer cells require a constant supply of nutrients, especially glucose and glutamine, to support their characteristic unabated growth [7] [8] [9] . Glutamine is essential for the growth of normal and neoplastic cells [3] . Interestingly, ASCT2 and the L-type amino acid transporter 1 (LAT1) are coordinately upregulated in a number of human cancers [6] . Moreover, a recent study reportedly revealed that ASCT2 and LAT1 exist in a plasma membrane complex with a monocarbonate transporter (collectively termed the "metabolic activation-related complex") in fibrosarcoma and breast and colon carcinoma cells [24] . We previously reported the molecular structure and distribution of canine LAT1 [15] . The data clarified in this report will contribute to an evaluation of the relationship between the expression level of these transporters and the malignancy of various types of canine cancer.
